The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996

Critical Reviews in Oncology/Hematology

Volumn 24, Issue 1, 1996, Pages 47-70

  O'Reilly, Seamus ^a   Rowinsky, Eric K ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; CYTARABINE; DNA TOPOISOMERASE; ETOPOSIDE; FLUOROURACIL; GYRASE INHIBITOR; IRINOTECAN;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; GYNECOLOGIC CANCER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; IONIZING RADIATION; LEUKEMIA; LEUKOPENIA; LUNG CANCER; LYMPHOMA; NAUSEA; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SKIN CANCER; STOMACH CANCER; VOMITING;

EID: 0030248494     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/1040-8428(96)00211-9     Document Type: Review

References (206)

1. [1] Wall ME, Wani MC. Camptothecin and Taxol: Discovery to Clinic - Thirteenth Bruce F Cain Memorial Award Lecture. Cancer Res 55:753-760, 1995.
2. [2] Muggia FM, Creaven PJ, Hansen H, Cohen MH, Selawry DS. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880). Correlation with preclinical studies. Cancer Chemother Rep 56:515-521, 1972.
3. [3] Gottlieb JA, Luce JK. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56:103-105, 1972.
4. [4] Moertel CG, Schutt AJ, Reitemeir RJ, Hahn RG. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95-101, 1972.
5. [5] Yokokura T, Sawada S, Nokata K et al. Antileukemic activity of new camptothecin derivatives. Proceedings of the Japanese Cancer Association, 40th Annual meeting. Japan: Sapparo, 1981; 228 (Abstract).
6. [6] Yokokura T, Furuta T, Sawada S et al. Anti-tumor activity of newly synthesised, lactone ring closed and water soluble camptothecin derivative in mice. Proceedings of the Japanese Cancer Association. 43rd Annual Meeting. Japan: Fukuoka, 1984; 261 (Abstract).
7. [7] Kunimoto T, Nitta K, Tanaka T et al. Anti-tumor activity of 7-ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxy camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944-5947, 1987.
8. [8] Gallo RC, Whang Peng J, Adamson RH. Studies on the anti-tumor activity, mechanism of action, and cell cycle effects of camptothecin, J Natl Cancer Inst 46:789-795, 1971.
9. [9] Vendetti JM. Treatment schedule dependency of experimentally active antileukemic (L1210) drugs. Cancer Chemother Rep 2:35-59, 1971.
10. [10] Schaeppi U, Fleischman RW, Cooney DA. Toxicity of camptothecin (NSC-100880). Cancer Chemother Rep 5:25-36, 1974.
11. [11] Wani MC, Ronman PE, Lindley JT et al. Plant anti-tumor agents. 18. Synthesis and biological activity of camptothecin analogues. J Med Chem 23:554-560, 1980.
12. [12] Gottlieb JA, Guarino AM, Call JB, Olivero VT, Block JB. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54:461-470, 1970.
13. [13] Stehlin JS, Natelson EA, Hinz HR et al. Phase I clinical trial and pharmacokinetic results with oral administration of 20 (S) camptothecin. In: Potmesil M, Pinedo H, eds. Camptothecins: New anticancer agents. Boca Raton FL: CRC Press, 1995; 59-65.
14. [14] Xu B, Chen J-T, Yang J-L et al. New results in pharmacologic research of some anticancer agents. In: Burns JJ, Tsuchitani PJ, eds. Proceedings of the US-China Pharmacologic Symposium. Committee on Scholarly Communication with the Peoples Republic of China. Washington DC: National Academy of Sciences, 1979; 151-158.
15. [15] Hertzberg PP, Caranfa MJ, Holden KG et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biologic activity. J Med Chem 32:715-720, 1989.
16. [16] Jaxel C, Kohn KW, Wani MC et al. Structure activity study of the actions of camptothecin derivatives on mammalian topoisomerase 1: evidence for a specific receptor site and a relation to anti-tumor activity. Cancer Res 49:1465-1469, 1989.
17. [17] Giovanella BC, Hinz HR, Kozielski AJ et al. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(s)-camptothecin. Cancer Res 51:3052-3055, 1991.
18. [18] Kingsbury WD, Boehm JC, Jakas DR et al. Synthesis of water soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase 1 and anti-tumor activity. J Med Chem 34:98-107, 1991.
19. [19] Hertzberg RP, Caranfa KJ, Holden RG et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32:715-720, 1989.
20. [20] Jenks S. Camptothecins resurface as promising drugs, J Natl Cancer Inst 86:1118-1120, 1994.
21. [21] Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as anti-tumor agents. J Natl Cancer Inst 85:271-291, 1993.
22. [22] Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 20:73-96, 1994.
23. [23] Takimoto CH, Arbuck SG. Camptothecins. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principals and Practice, 2nd Edn. Philadelphia PA: Lippincott Raven Publishers, 1996; 463-484.
24. [24] Burris HA, Fields SM. Topoisomerase I inhibitors. An overview of the camptothecin analogs. Heme Onc Clin North Am 8:333-355, 1994.
25. [25] Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res 54:1431-1439, 1994.
26. [26] Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 33:2834-2836, 1973.
27. [27] Sparato A, Kessel D. The effects of camptothecin on mammalian DNA. Biochem Biophys Acta 331:194-201, 1973.
28. [28] Stevnsner T, Bohr VA. Studies on the role of topoisomerases in general, gene and strand specific DNA repair. Carcinogenesis 14:1841-1850, 1993.
29. [29] Tsao YP, Russo A, Nyamuswa G, Silber R, Liu LF. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell free SV40 DNA replication system. Cancer Res 53:5908-5914, 1993.
30. [30] Li LH, Fraser TJ, Olin EJ et al. Action of camptothecin on mammalian cells in culture. Cancer Res 32:2643-2650, 1972.
31. [31] D'Arpa P, Beardmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50:6919-6924, 1990.
32. [32] Kawato J, Aonuma M, Hirito Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the anti-tumor effect of CPT-11. Cancer Res 51:4187-4191, 1991.
33. [33] Kawato Y, Aonuma M, Hirota Y et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumour effect of CPT-11. Cancer Res 51:4187-4191. 1991.
34. [34] Kanzawa F, Kondoh H, Kwon SJ et al. Role of carboxylesterase on metabolism of camptothecin analogue (CPT-11) in non-small-cell lung cancer cell line PC-7 cells. Proc Am Assoc Cancer Res 33:427, 1992 (Abstract).
35. [35] Kaneda N, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50:1715-1720, 1990.
36. [36] Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 14:341-349, 1991.
37. [37] Satoh T, Hosokawa M, Atsumi R, Suzuki N, Hakusui H, Nagai E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(piperidino)-1-piperidino] carbonyloxycamptothecin; a novel anti-tumor agent, by carboxylesterase. Biol Pharm Bull 17:662-664, 1994.
38. [38] Chen SF, Rothenberg ML, Clark G et al. Human carboxylesterase activity correlates with CPT-11 cytotoxicity in vitro. Proc Am Assoc Cancer Res 35:365, 1994 (Abstract).
39. [39] Fassberg J, Stella VJ. A kinetic and mechanistic study of hydrolysis of camptothecin and some analogues. J Pharmacol Sci 81:676-684, 1992.
40. [40] Rivory LP, Chatelut E, Canal P, Mathieu-Boue A, Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of Irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 54:6330-6333, 1994.
41. [41] Burke TG, Mi Z. Ethyl substitution at the 7 position extends the half life of 10-hydroxycamptothecin in the presence of human serum albumin. J Med Chem 36:2580-2582, 1993.
42. [42] Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37:40-46, 1994.
43. [43] Tsao YP, D'Arpa P, Liu L. The involvement of active DNA synthesis in camptothecin induced G2 arrest: altered regulation of p34 cdc2/cyclin B1. Cancer Res 52:1823-1829, 1992.
44. [44] Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Unscheduled activation of cyclin B1/cdc2 kinase in human promyelocytic leukemia cell line HL-60 cells undergoing apoptosis induced by DNA damage. Cancer Res 55:228-231, 1995.
45. [45] McSheehy PM, Gervasoni M, Lampasona V, Erba E, D'Incalci M. Studies on the differentiation properties of camptothecin in the human leukemic cells K562. Eur J Cancer 27:1406-1411, 1991.
46. [46] Aller P, Rius C, Mata F et al. Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemia cells. Cancer Res 52:1245-1251, 1992.
47. [47] Chou S, Kaneko M, Nakaya K et al. Induction of differentiation of human and mouse myeloid leukemia cells by camptothecin. Biochem Biophys Res Commun 166:160-167, 1990.
48. [48] Wani MA, Snapka RM. Drug induced loss of unstably amplified genes. Cancer Invest 8:587-593, 1990.
49. [49] Onishi Y, Azuma Y, Sato Y, Mizuno Y, Tadakuma T, Kizaki H. Topoisomerase inhibitors induce apoptosis in thymocytes. Biochim Biophys Acta 1175:147-152, 1993.
50. [50] Solary E, Bertrand R, Kohn KW, Pommier Y. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood 81:1359-1368, 1993.
51. [51] Bertrand R, Solary E, Jenkins J, Pommier Y. Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors. Exp Cell Res 207:388-397, 1993.
52. [52] Traganos F, Kapuscinski J, Gong J, Ardelt B, Darzynkiewicz RJ, Darzynkiewicz Z. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells. Cancer Res 53:4613-4618, 1993.
53. [53] Li X, Traganos F, Darzynkiewicz Z. Simultaneous analysis of DNA replication and apoptosis during treatment of HL-60 cells with camptothecin and hyperthermia, and mitogen stimulation of human lymphocytes. Cancer Res 54:4289-4293, 1994.
54. [54] Gong J, Li X, Darnzynkiewicz Z. Different patterns of apoptosis of HL-60 cells induced by cycloheximide and camptothecin. J Cell Physiol 157:263-270, 1993.
55. [55] Del Bino G, Bruno S, Yi PN, Darzynkiewicz Z. Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell Prolif 25:537-548, 1992.
56. [56] Del Bino G, Li X, Traganos F, Darzynkiewicz Z. Altered susceptibility of differentiating HL60 cells to apoptosis induced by anti-tumor drugs. Leukemia 8:281-288, 1994.
57. [57] Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14:1815-1823, 1994.
58. [58] Kessel D. Some determinants of camptothecin responsiveness in leukemia L1210 cells. Cancer Res 31:1883-1887, 1971.
59. [59] Johnson RK, Chitnis MP, Embrey WM et al. In vivo characteristics of resistance and cross resistance of an adriamycin resistant subline of P388 leukemia. Cancer Treat Rep 62:1535-1547, 1978.
60. + + dependent binding of vincristine to the plasma membrane of multidrug resistant k562 cells. J Biol Chem 263:11887-11891, 1988.
61. [61] Chen AY, Yu C, Potsmeil M et al. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51:6039-6044, 1991.
62. [62] Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH. Effects of P-glycoprotein expression on accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52:2268-2278, 1992.
63. [63] Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Anti-tumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21:71-74, 1988.
64. [64] Lai SL, Goldstein L, Gottesman M et al. MDR1 gene expression in lung cancer. J Natl Cancer Inst 81:1144-1150, 1989.
65. [65] Goldstein L, Galski H, Fojo A et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116-124, 1989.
66. [66] Fojo A, Ueda K, Slamon D et al. Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269, 1987.
67. [67] Thiebaut F, Tsuruo T, Hameda H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738, 1987.
68. [68] Van der Valk P, Van Kalken CK, Ketelaars H et al. Distribution of multidrug resistance associated P glycoprotein in normal and neoplastic human tissue. Ann Oncol 1:56-64, 1990.
69. [69] Niimi S, Nakagawa K, Sugimoto Y et al. Mechanisms of cross resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res 52:328-333, 1992.
70. [70] Kanzawa F, Sugimoto Y, Minato K et al. Establishment of a camptothecin analogue (CPT-11) resistant cell line of human non-small-cell lung cancer: characterisation and mechanism of resistance. Cancer Res 50:5919-5924, 1990.
71. [71] Oyama H, Nagane M, Shibui S, Nomura K, Mukai K. Intracellular distribution of CPT-11 in CPT-11-resistant cells with confocal laser scanning microscopy. Jpn J Clin Oncol 22:331-334, 1992.
72. [72] Sugimoto Y, Tsukahara S, Oh-Hara T, Isoe T, Tsunio T. Decreased expression of topoisomerase I in camptothecin resident tumor cell lines as determined by monoclonal antibody. Cancer Res 50:6925-6930, 1990.
73. [73] Kijima T, Kubota N, Nishio K. Establishment of a CPT-11 resistant human ovarian cancer cell line. Anticancer Res 14:799-803, 1994.
74. [74] Chang J-Y, Dethletsen LA, Barley LR, Zhou BS, Cheng Y-C. Characterization of camptothecin resistant Chinese Hamster lung cells. Biochem Pharmacol 43:2443-2452, 1992.
75. [75] Gupta RS, Gupta R, Eng B et al. Camplothecin resistant mutants of chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 48:6404-6410, 1988.
76. [76] Fujimori A, Graydon Harker W, Kohlhagen G, Hoki Y, Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res 55:1339-1346, 1995.
77. [77] Tanizawa A, Pommier Y. Topoisomerase I alteration in a camptothecin resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res 52:1848-1854, 1992.
78. [78] Andoh T, Ishii K, Suzuki Y et al. Characterisation of a mammalian mutant with a camptothecin-resistanl DNA topoiomerase I. Proc Natl Acad Sci USA 84:5565-5569, 1987.
79. [79] Kjeldsen E, Bonven BJ, Andoh T et al. Characterisation of a camptothecin resistant human DNA topoisomerase I. J Biol Chem 263:3912-3916, 1988.
80. [80] Tamura H, Konichi C, Yamada R et al. Molecular cloning of a cDNA of a camptothecin resistant human DNA topoisomerase I and identification of mutation sites. Nucl Acids Res 19:69-75, 1991.
81. [81] Tan KB, Mattern MR, Eng WK et al. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81:1732-1735, 1989.
82. [82] Vaughan W, Karp J, Burke P. Long chemotherapy free remission after single cycle timed sequential chemotherapy for acute myelocytic leukemia. Cancer 45:859-865, 1980.
83. [83] Rowinsky EK, Sartorius S, Grochow L et al. Phase I and pharmacologic study of topotecan, an inhibitor of topoiomerase I with granulocyte colony stimulating factor (G-CSF): toxicologic differences between concurrent and post treatment G-CSF administration. Proc Am Soc Clin Oncol 11:116, 1992 (Abstract).
84. [84] Lowe SW, Ruley HE, Jacks T et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993.
85. [85] Sen S, D'Incalci M. Apoptosis. Biochemical events and relevance and relevance to cancer chemotherapy. FEBS Lett 307:122-127, 1992.
86. [86] Sorensen CM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82:749-755, 1990.
87. [87] O'Connor PM, Kohn KW. A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells? Semin Cancer Biol 3:409-416, 1992.
88. [88] Cotter TG, Glynn JM, Echeverri F. The induction of apoptosis by chemotherapeutic agents occurs in all phases of the cell cycle. Anticancer Res 12:773-779, 1992.
89. [89] Ohmori T, Podack ER, Nishio K et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 192:30-36, 1993.
90. [90] Walton MI, Whysong D, O'Connor PM, Hockenberg D, Korsmeyer SJ, Kohn KW. Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53:1853-1861, 1993.
91. [91] Eng W-K, Faucette LF, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34:755-760, 1988.
92. [92] Furuta T, Yokokura T, Mutai M. Anti-tumor activity of CPT-11 against rat Walker 256 carcinoma. Jpn J Cancer Chemother 15:2757-2760, 1988.
93. [93] Bissery MC, Mathieu-Boue A, Lavelle F. Preclinical evaluation of CPT-11, a camptothecin derivative. Proc Am Assoc Cancer Res 32:402, 1991 (Abstract).
94. [94] Bissery MC, Mathieu-Boue A, Lavelle F. Experimental anti-tumor activity of CPT-11 in vivo and in vitro. In: Proceedings of the Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, 1992: 82 (Abstract).
95. [95] Matsuzaki T, Yokokura T, Mutai M et al. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21:308-312, 1988.
96. [96] Kawato Y, Furuta T, Aonuma M et al. Anti-tumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 28:192-198, 1991.
97. [97] Wang Y, Inoue K, Shibata H. Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay. Jpn J Cancer Chemother 14:1264-1270, 1987.
98. [98] Shimada Y, Rothenberg M, Hilsenbeck SG, Burris HA III, Deagen D, Von Hoff DD. Activity of CPT-11 (Irinotecan hydrochloride); a topoisomerase I inhibitor, against human tumor colony forming units. Anticancer Drugs 5:202-206, 1994.
99. [99] Matsuoka H, Furusaira M, Tomoda H et al. Cytotoxicity of CPT-11 and SN-38 for gastrointestinal and recurrent carcinomas cultured on contact sensitive plates. Anticancer Res 14:405-409, 1994.
100. [100] Hare CB, Elion GB, Houghton P et al. Treatment of central nervous sytem xenografts with CPT-11. Proc Am Assoc Cancer Res 37:433, 1996 (Abstract).
101. [101] Boothman DA, Trask DK, Pardee AB. inhibition of potentially lethal damage repair in human tumor cells by beta lapachone, an activator of topoisomerase I. Cancer Res 49:605-612, 1987.
102. [102] Ng CE, Bussey AM, Raaphorst GP. Inhibition of potentially lethal and sublethal damage by camptothecin and etoposide in human melanoma cell lines. Int J Radiat Biol 66:49-57, 1994.
103. [103] Lamond JP, Kirwin R, Wall ME, Boothman DA. Topoiomerase I inhibitors potentiate radiation lethality in vitro. Proc Am Assoc Cancer Res 36:441, 1995 (Abstract).
104. [104] Boothman DA, Wang M, Schea RA, Burrows HL, Strickfaden S, Owens JK. Post-treatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant malignant melanoma cells. Int J Radiat Oncol Biol Phys 24:939-948, 1992.
105. [105] Mattern MR, Hoffman GA, McCabe FL, Johnson RK. Synergistic cell killing by ionizing radiation and topoiomerase I inhibitor topotecan (SK&F 104864). Cancer Res 51:5813-5816, 1991
106. [106] Pantazis P. Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments. Clin Cancer Res 1:1235-1244, 1995.
107. [107] Boscia RE, Korbut T, Holden SA, Ara G, Teicher BA. Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int J Cancer 53:118-123, 1993.
108. [108] Falk SJ, Smith PJ. DNA damaging and cell cycle effects of the topoiomerase I poison camptothecin in irradiated human cells. Int J Radiol Biol 61:749-757, 1992.
109. [109] Hennequin C, Giocanti N, Balosso J, Favaudon V. Interaction of ionizing radiation with topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res 54:1720-1728, 1994.
110. [110] Katz EJ, Vick JS, Kling KM et al. Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur J Cancer 26:724-727, 1990.
111. [111] Drewinko B, Green C, Loo TL. Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II). Cancer Treat Rep 60:1619-1625, 1976.
112. [112] Johnson R, Mc Cabe F, Yu Y. Combination regimens with topotecan in animal tumor models. In: Proceedings of the Seventh NC1-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam, 1992; 85 (Abstract).
113. [113] Kudoh S, Takada M, Masuda N et al. Enhanced anti-tumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 84:203-207, 1993.
114. [114] Kano Y, Suzuki K, Akutsu M et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50:604-610, 1992.
115. [115] Minagawa Y, Kigawa J, Ishihari H, Itamochi H, Terakawa N. Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn J Cancer Res 85:966-971, 1994.
116. [116] Akutsu M, Suzuki K, Tsunoda S, Kano Y, Miura Y. Effects of SN-38 in combination with other anticancer agents against Dauji cells. Jpn J Cancer Chemother 21:1607-1611, 1994.
117. [117] Oguoro M. A topoisomerase I inhibitor CPT-11: its enigmatic anti-tumor activity in combination with other agents in vitro. In: Proceedings of the Third Conference on Topoiomerases, 1990; 35 (Abstract).
118. [118] Bertrand R, O'Connor PM, Kerrigan D, Pommier Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28A:743-748, 1992.
119. [119] Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs. A cautionary note. Cancer Res 49:5870-5878, 1989.
120. [120] Anzai H, Frost P, Abbruzzese JL. Synergistic cytotoxicity with combined inhibition of topoiomerase I and II. Proc Am Assoc Cancer Res 33:431, 1992 (Abstract).
121. [121] Kim R, Hirabayashi N, Nishyama M et al. Experimental studies on biochemical modulation targeting topoiomerase I and II in human tumor xenografts in nude mice. Int J Cancer 50:760-766, 1992.
122. [122] Funakoshi S, Aiba K, Shibata H et al. Enhanced antitumor activity of SN-38, an active metabolite of CPT-11, and fluorouracil combination for human colorectal cancer cell lines. Proc Am Soc Clin Oncol 12:193, 1993 (Abstract).
123. [123] Guichard S, Cliaro MJ, Houin G, Bugat R, Canal P. Sequential exposure to CPT-11 and 5-FU is synergistic in human colon carcinoma HT-29 cell line. Proc Am Assoc Cancer Res 37:292, 1996 (Abstract).
124. [124] Kaneda N, Yokokura T. Non-linear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721-1725, 1990.
125. [125] Rothenberg ML, Kuhn JG, Burris HA et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993.
126. [126] Rowinsky EK, Grochow LB, Ettinger DS et al. Phase I and pharmacologic study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a 90-minute infusion every 3 weeks. Cancer Res 54:427-436, 1994.
127. [127] Negoro S, Fukuoka M, Masuda N et al. Phase I study of weekly administration of CPT-11. J Natl Cancer Inst 83:1164-1168, 1991.
128. [128] Ohe Y, Sasaki Y, Shinkai T et al. Phase I and pharmacokinetic study of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 12:972-974, 1992.
129. [129] Sasaki Y, Morita M, Miya T et al. Pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Proc Am Soc Clin Oncol 11:264, 1992 (Abstract).
130. [130] deForni M, Bugat R, Chabot GC et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347-4354, 1994.
131. [131] Abigerges D, Chabot GC, Armand JP, Herait P, Gouyette A and Gandia D. Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221, 1995
132. [132] Gay C, Lokiec F, Canal P, Bonneterre J, Bugat R, Tubiana-Hulin M, Matthieu-Boue. Pharmacokinetics and pharmacodynamics of the camptothecin analogue CPT-11 during phase II studies. Proc Am Assoc Cancer Res 35:243, 1994 (Abstract).
133. [133] Rivory LP, Robert J. Reversed phase high performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr 661:133-141, 1994.
134. [134] Chabot GG, Abigerges D, Catimel G et al. Population pharmacokinetics and pharmacodynamics of irinotecan and its active metabolite during phase I trials. Ann Oncol 6:141-151, 1995.
135. [135] Investigators Brochure CPT-11. Princeton NJ: GH Besselaar Associates, 1991.
136. [136] Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 84:697-702, 1993.
137. [137] Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725, 1994.
138. [138] Gupta E, Mick R, Wang X, Vokes EE, Ratain MJ. Pharmacokinetic-pharmacodynamic analysis of intestinal toxicity associated with irinotecan: validation of biliary index. Ann Oncol 7(Suppl 1):129, 1996 (Abstract).
139. [139] Mick R, Gupta E, Vokes EE, Ratain MJ. Limited sampling model for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and its resulting intestinal toxicity. Ann Oncol 7(Suppl 1):129, 1996 (Abstract).
140. [140] Gupta E, Safa AR, Ratain MJ. p Glycoprotein mediated excretion of CPT-11 and SN-38: effect of cyclosporin A. Proc Am Soc Clin Oncol 14:490, 1995 (Abstract).
141. [141] Taguchi T, Wakui A, Hasegawa K et al. Phase I clinical study of CPT-11. Jpn J Cancer Chemother 17:115-120, 1990.
142. [142] Fukuoka M, Negoro S, Niitani H et al. A phase I study of weekly administration of CPT-11 in lung cancer. Jpn J Cancer Chemother 17:993-997, 1991.
143. [143] Lestingi TM, Vokes EE, Gray W et al. A phase I trial of CPT-11 in solid tumors with G-CSF and antidiarrheal support. Proc Am Soc Clin Oncol 14:480, 1995 (Abstract).
144. [144] Catimel G, Chabot GG, Guastalla JP et al. Phase I and pharmacokinetic study of irinotecan administered daily for 3 consecutive days every 3 weeks in patients with advanced cancer. Ann Oncol 6:133-140, 1995.
145. [145] Abigerges D, Armand JP, Chabot GG et al. Irinotecan, high dose escalation using intensive high dose loperamide to control diarrhea. J Natl Cancer Inst 86:446-449, 1994.
146. [146] Misset JL, Saliba F, Giachetti S et al. Pathophysiology and therapy of irinotecan induced delayed diarrhea: a prospective assessment. Ann Oncol 7(Suppl 1):128, 1996 (Abstract).
147. [147] Gonclaves E, da Costa L, Abigerges D, Armand JP. A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11. J Clin Oncol 13:2144-2146, 1996.
148. [148] Ychou M, Rougier Ph, Douillard JY et al. A phase II study of CPT-11 in colorectal cancer refractory to 5-FU, with preventative treatment of delayed toxicity using acetorphan. Ann Oncol 7(Suppl 1):128, 1996 (Abstract).
149. [149] Negoro S, Fukuoka M, Niitani H et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 18:1013-1019, 1991.
150. [150] Nakai H, Fukuoka M, Furese K et al. An early phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother 18:607-612, 1991.
151. [151] Fukuoka M, Niitani H, Suzuki A et al. A phase II trial of CPT-11, a new derivative of camptothecin for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16-20, 1992.
152. [152] Douillard JY, Ibrahim N, Riviere A et al. Phase II study of CPT-11 in non-small-cell lung cancer. Proc Am Soc Clin Oncol 14:365, 1995 (Abstract).
153. [153] Masuda N, Fukuoka M, Kusunoki Y et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992.
154. [154] Shimada Y, Yoshina M, Wakui A et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993.
155. [155] Conti JA, Kemeny N, Saltz L et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715, 1996.
156. [156] Pitot HC, Wender D, O'Connell MJ, Wieand HS, Maillard JA. A phase II trial of CPT-11 in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group Study. Proc Am Soc Clin Oncol 13:197, 1994 (Abstract).
157. [157] Rothenberg ML, Eckardt JR, Burris HA et al. Irinotecan as second line therapy for patients with 5-FU refractory colorectal cancer. Proc Am Soc Clin Oncol 13:198, 1994 (Abstract).
158. [158] Bugat R, Suc E, Rougier Ph et al. CPT-11 as second line therapy in advanced colorectal cancer: preliminary results of a multicentric phase II study. Proc Am Soc Clin Oncol 13:200, 1994 (Abstract).
159. [159] Bugat R, Rougier Ph, Douillard JY et al. Efficacy of irinotecan in patients with metastatic colorectal cancer after progression while receiving a 5-FU based chemotherapy. Proc Am Soc Clin Oncol 14:222, 1995 (Abstract).
160. [160] Van Cutsem E, Cunningham D, ten Bokkel Huinink W et al. Irinotecan multicenter phase II study in patients with 5-FU resistant colorectal cancer: preliminary analysis. Ann Oncol 7(Suppl 1):128, 1996 (Abstract).
161. [161] Takeuchi S, Takamaizawa H, Takeda Y et al. An early phase II study of CPT-11 for gynecologic cancers. Jpn J Cancer Chemother 18:579-584, 1991.
162. [162] Takeuchi S, Takamizawa H, Takeda Y et al. Clinical study of CPT-11, camptothecin derivative, on gynecological malignancy. Proc Am Soc Clin Oncol 10:189, 1991 (Abstract).
163. [163] Takeuchi S, Dobashi K, Fujimoto S et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Jpn J Cancer Chemother 18:1681-1689, 1991.
164. [164] Takeuchi S, Noda K, Yakushiji M and the CPT-11 group on gynecologic maliganancy. Late phase II study of CPT-11, topoisomerase I inhibitor, in advanced cervical carcinoma. Proc Am Soc Clin Oncol 11:234, 1992 (Abstract).
165. [165] Kavanagh JJ, Kudelka AP, Edwards CE, Girtanner RE, Durivage HF, Howell ET. CPT-11: phase II study in refractory squamous carcinoma of the cervix. Proc Am Assoc Cancer Res 35:234, 1994 (Abstract).
166. [166] Chevallier B, L'Homme C, Dieras V et al. Phase II trial of CPT-11 in advanced cervical cancer. Proc Am Soc Clin Oncol 14:267, 1995 (Abstract).
167. [167] Potkul RK, Price FV, Bailey H et al. Irinotecan (CPT-11) in advanced squamous cell cancer of the cervix a phase II trial. Proc Am Soc Clin Oncol 14:279, 1995.
168. [168] Sugiyama T, Takeuchi S, Noda K, Yakushiji M and the CPT-11 Study Group on Gynecologic Maligancy. Phase I study of irinotecan in combination with cisplatin on cervical carcinoma. Proc Am Soc Clin Oncol 13:268, 1994 (Abstract).
169. [169] Ohno R, Okada K, Masaoka T et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907-1912, 1990.
170. [170] Tauda H, Takatsuki K, Ohno R et al. A late phase II trial of a potent topoisomerase I inhibitor CPT-11, in malignant lymphoma. Proc Am Soc Clin Oncol 11:1070, 1992 (Abstract).
171. [171] Tsuda H, Takatsuki K, Ohno R et al. Treatment of adult T cell leukemia-lymphoma with irinotecan hydrochloride (CPT-11). Br J Cancer 70:711-714, 1994.
172. [172] Bonneterre J, Pion JM, Adenis A et al. A phase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients. Proc Am Soc Clin Oncol 12:94, 1993 (Abstract).
173. [173] Lokiec F, Mathieu Boue A, Canal P et al. Breast cancer phase II-pharmacokinetic study of a new pharmacokinetic derivative CPT-11. Proc Am Assoc Cancer Res 34:2362, 1993 (Abstract).
174. [174] Taguchi T, Yoshida Y, Izuo M et al. An early phase II study of CPT-11 in patients with advanced breast cancer. Jpn J Cancer Chemother 21:83-90, 1994.
175. [175] Taguchi T, Tominaga T, Ogawa M, Ishida T, Morimoto K, Ogawa N. A late phase II study of CPT-11 in advanced breast cancer. Jpn J Cancer Chemother 21:1017-1024, 1994.
176. [176] Sakata Y, Wakui A, Nakao I et al. A late phase II study of irinotecan in advanced pancreatic cancer. Proc Am Soc Clin Oncol 12:211, 1993 (Abstract).
177. [177] Wagener DJTh, Verdonk HER, Dirix LY et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC Early Clinical Trials Group Study. Ann Oncol 6:129-132, 1995.
178. [178] Kambe M, Wakui A, Nakao I et al. A late phase II study of irinotecan in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 12:198, 1993 (Abstract).
179. [179] Shirao K, Shimada Y, Kondo H et al. Phase I study of CPT-11 combined with cisplatin for metastatic gastric cancer. Proc Am Soc Clin Oncol 13:215, 1994 (Abstract).
180. [180] Ishihara K, Ikeda S, Ohura T et al. Early phase II study of irinotecan (CPT-11) in skin cancer. Skin Cancer 7:382-388, 1992.
181. [181] Ikeda S, Ishihara K, Ohura T, Takahashi M, Ohtsuka F, Tamaoki K. Late phase II study of irinotecan (CPT-11) in squamous carcinoma of the skin and malignant melanoma. Skin Cancer 8:503-513, 1993.
182. [182] Masuda N, Fukuoka M, Takada M et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10:1775-1780, 1992.
183. [183] Masuda N, Fukuoka M, Kudoh S et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for achanced lung cancer. Br J Cancer 68:777-782, 1993.
184. [184] Masuda N, Fukuoka M, Kudoh S et al. Phase I study of irinotecan and cisplatin with granulocyte colony stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 12:90-96, 1994.
185. [185] Fujiwara Y, Yamakido M, Fukuoka M et al. Phase II study of irinotecan and cisplatin in patients with small-cell lung cancer. Proc Am Soc Clin Oncol 13:335, 1994 (Abstract).
186. [186] Sumiyoshi H, Fujiwara Y, Ohashi N, Egusa Y, Yamaoka N, Yamakiodo M. Clinical pharmacological evaluation of CPT-11 and cisplatin in patients with small-cell lung cancer. Proc Am Soc Clin Oncol 14:457, 1995.
187. [187] Mori K, Suga U, Kishora I, Ohta S, Tominaga K. A phase I study of CPT-11 and cisplatin (5-day continuous infusion) for advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 13:366, 1994 (Abstract).
188. [188] Shinkai T, Arioka H, Kunikane H et al. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small-cell lung cancer. Cancer Res 54:2636-2642, 1994.
189. [189] Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF, Tsuruo T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50:7962-7965.
190. [190] Tan KB, Mattern MR, Eng W-K, McCabe FL, Johnson RK. Non-productive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81:1732-1735, 1989.
191. [191] Karato A, Sasaki Y, Shinkai T et al. Phase I study of CPT-11 and etoposidc in patients with refractory solid tumors. J Clin Oncol 11:2030-2035, 1993.
192. [192] Masuda N, Fukuoka M, Kudoh S et al. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 12:1833-1841, 1994.
193. [193] Goto K, Nishiwaki Y, Saijo N et al. A phase II study of irinotecan and etoposide for metastatic non-small-cell lung cancer: Japanese Clinical Oncology Group Trial. Proc Am Soc Clin Oncol 14:362, 1995 (Abstract).
194. [194] Shimada Y, Sasaki Y, Sugano K et al. Combination phase I study of CPT-11 combined with continuous infusion 5-FU in metastatic colorectal cancer. Proc Am Soc Clin Oncol 12:575, 1993 (Abstract).
195. [195] Sasaki Y, Ohtsu A, Shimada Y, Ono K, Saijo N. Simultaneous administration of CPT-11 and fluorouracil; alteration of the pharmacokinetics of CPT-11 and SN38 in patients with advanced colorectal cancer. J Natl Cancer Inst 86:1096-1098, 1994.
196. [196] Saltz L, Kanowitz J, Kemeny N et al. Phase I trial of irinotecan, 5-fluorouracil, and leucovorin in patients with advanced solid tumors. Proc Am Soc Clin Oncol 14:476, 1995 (Abstract).
197. [197] Tait N, Parnes H, Van Echo DA. Aphase I multischedule study of CPT-11, 5 FU and leucovorin in advanced cancer. Ann Oncol 7(Suppl 1):130, 1996 (Abstract).
198. [198] Rixe O, Benhammouda A, Farabos C et al. Concomitant CPT-11 and 5FU combination: a phase I study. Ann Oncol 7(Suppl 1):129, 1996 (Abstract).
199. [199] Chabot GG. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38. Cancer Chemother Pharmacol 36:463-472, 1995.
200. [200] Takasuna K, Kasai Y, Kitano Y et al. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative irinotecan hydrochloride in rats. Jpn J Cancer Res 86:978-984, 1995.
201. [201] Hagipaantelli R, Saliba F, Misset JL et al. Pathophysiology and therapy of irinotecan induced delayed diarrhea: a prospective assessment. Proc Am Soc Clin Oncol 14:464, 1995 (Abstract).
202. [202] Rowinsky E, Grochow L, Kaufmann S et al. Sequence dependent effects of topotecan and cisplatin in a phase I and pharmacologic study. Proc Am Soc Clin Oncol 13:142, 1994 (Abstract).
203. [203] Mc Govren JP, DeKoning TF, Mattern SJ, Ratke CC, Shobe EM, Yancey MF. Oral antitumor efficacy and bioavailability of irinotecan in the mouse: enhancement of efficacy by protracted oral administration. Ann Oncol 7(Suppl 1):127, 1996 (Abstract).
204. [204] Ratke CC, Stewart NL, Stout CL, Yancey MF, Shobe EM. Comparative intravenous and oral toxicity and pharmacokinetics study in dogs with irinotecan, a topoisomerase I inhibitor. Ann Oncol 7(Suppl 1):128, 1996 (Abstract).
205. [205] Armand JP, Ducreux M, Mahjoubi M et al. CPT-11 in the treatment of colorectal cancer. Eur J Cancer 31A:1283-1287, 1995.
206. [206] Ardizzoni A. Camptothecin analogues in the treatment of non-small cell lung cancer. Lung Cancer 12(Suppl 1):S177-185, 1995.